fluphenazine has been researched along with Dyskinesia Syndromes in 68 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Reserpine treatment increased VCMs and decreased locomotor activity." | 5.39 | Effect of Hypericum perforatum on different models of movement disorders in rats. ( Athayde, ML; Boligon, AA; Busanello, A; Fachinetto, R; Leal, CQ; Reckziegel, P; Reis, EM; Röpke, J; Wagner, C, 2013) |
| "Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone." | 5.11 | Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. ( Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004) |
| "Injected intramuscularly, the enanthane and decanoate esters of the phenothiazine fluphenazine are an effective treatment of the disordered behavior and thinking of schizophrenia." | 3.65 | The long-acting phenothiazines. ( Groves, JE; Mandel, MR, 1975) |
| " Improvement was recorded in a double blind study of 18 patients treated with maximum tolerated dosage (mean 18." | 2.64 | Tardive dyskinesia treated with pimozide. ( Calne, DB; Claveria, LE; Haskayne, L; Lodge-Patch, IC; Pallis, CA; Petrie, A; Teychenne, PF, 1975) |
| "Acute withdrawal is therefore unjustified, but occasional revision of dosage of anti-Parkinsonian drugs is advisable." | 2.64 | Benzhexol and side effects with long-acting fluphenazine therapy. ( Crammer, JL; Grove, L, 1972) |
| "Acute dystonia can also be reliably induced in many primate species by neuroleptic treatment with comparable time course, symptomatology and pharmacological characteristics to those observed in man." | 2.37 | Acute dystonia induced by neuroleptic drugs. ( Jenner, P; Marsden, CD; Rupniak, NM, 1986) |
| "Reserpine treatment increased VCMs and decreased locomotor activity." | 1.39 | Effect of Hypericum perforatum on different models of movement disorders in rats. ( Athayde, ML; Boligon, AA; Busanello, A; Fachinetto, R; Leal, CQ; Reckziegel, P; Reis, EM; Röpke, J; Wagner, C, 2013) |
| "Schizophrenia is thought to be the psychiatric diagnosis the most frequently associated with TD." | 1.39 | [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics]. ( Bellaaj, R; Bouguerra, C; Gallali, S; Mehdi, F; Oumaya, A; Sejil, I, 2013) |
| "Fluphenazine treatment produced VCM in 70% of rats and the concomitant treatment with resveratrol decreased the prevalence to 30%, but did not modify the intensity of VCMs." | 1.38 | Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine. ( Barbosa, NB; Busanello, A; Fachinetto, R; Pereira, RP; Peroza, LR; Prestes, Ade S; Rocha, JB; Sudati, JH; Wagner, C, 2012) |
| "Rats treated with fluphenazine had significantly lower neuron densities than those that did not receive antioxidants." | 1.31 | Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytochemical methods. ( Browning, JA; Caligiuri, MP; Lohr, JB; Manley, MS, 2000) |
| " The mean dosage of the drug was 25-50 mg per 3-4 weeks." | 1.27 | [Long-term moditen-depot treatment of schizophrenic patients at a psychoneurology dispensary]. ( Abramova, LI; Gushanskiĭ, EL, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 61 (89.71) | 18.7374 |
| 1990's | 1 (1.47) | 18.2507 |
| 2000's | 2 (2.94) | 29.6817 |
| 2010's | 4 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wise, LD | 1 |
| Butler, DE | 1 |
| DeWald, HA | 1 |
| Lustgarten, D | 1 |
| Coughenour, LL | 1 |
| Downs, DA | 1 |
| Heffner, TG | 1 |
| Pugsley, TA | 1 |
| Reis, EM | 1 |
| Röpke, J | 1 |
| Busanello, A | 2 |
| Reckziegel, P | 1 |
| Leal, CQ | 1 |
| Wagner, C | 2 |
| Boligon, AA | 1 |
| Athayde, ML | 1 |
| Fachinetto, R | 2 |
| Peroza, LR | 1 |
| Sudati, JH | 1 |
| Pereira, RP | 1 |
| Prestes, Ade S | 1 |
| Rocha, JB | 1 |
| Barbosa, NB | 1 |
| Chrisphonte, P | 1 |
| Ostroff, RB | 1 |
| Rosenheck, RA | 1 |
| Sejil, I | 1 |
| Oumaya, A | 1 |
| Bouguerra, C | 1 |
| Mehdi, F | 1 |
| Bellaaj, R | 1 |
| Gallali, S | 1 |
| SCHNETZLER, JP | 1 |
| LAMAND, JC | 1 |
| CASSASSUCE, J | 1 |
| HAEFNER, H | 1 |
| KUTSCHER, I | 1 |
| KRUSE, W | 1 |
| ECKMANN, F | 1 |
| IMMICH, H | 1 |
| LERNER, J | 1 |
| Turner, M | 1 |
| Eerdekens, E | 1 |
| Jacko, M | 1 |
| Eerdekens, M | 1 |
| Irwin, S | 1 |
| Terry, PM | 1 |
| Lowther, J | 1 |
| Tune, LE | 1 |
| Coyle, JT | 1 |
| Escobar, JI | 1 |
| Barron, A | 1 |
| Kiriakos, R | 1 |
| Marder, SR | 1 |
| Van Putten, T | 1 |
| Mintz, J | 1 |
| McKenzie, J | 1 |
| Lebell, M | 1 |
| Faltico, G | 1 |
| May, PR | 1 |
| Folstein, S | 1 |
| Folstein, M | 1 |
| Jackson-Lewis, V | 1 |
| Przedborski, S | 1 |
| Lohr, JB | 1 |
| Caligiuri, MP | 1 |
| Manley, MS | 1 |
| Browning, JA | 1 |
| Curry, SH | 1 |
| Altamura, AC | 1 |
| Montgomery, S | 1 |
| Siggins, GR | 1 |
| Henriksen, SJ | 1 |
| Landis, SC | 1 |
| Claveria, LE | 1 |
| Teychenne, PF | 1 |
| Calne, DB | 1 |
| Haskayne, L | 1 |
| Petrie, A | 1 |
| Pallis, CA | 1 |
| Lodge-Patch, IC | 1 |
| Groves, JE | 1 |
| Mandel, MR | 1 |
| Alevizos, B | 1 |
| Ayd, FJ | 3 |
| Marriett, PF | 1 |
| Ogita, K | 1 |
| Yagi, G | 1 |
| Itoh, H | 1 |
| Stimmel, GL | 1 |
| Jankovic, J | 1 |
| Caskey, TC | 1 |
| Stout, JT | 1 |
| Butler, IJ | 1 |
| Rupniak, NM | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Abramova, LI | 1 |
| Gushanskiĭ, EL | 1 |
| Fleming, P | 1 |
| Makar, H | 1 |
| Hunter, KR | 1 |
| Kihara, H | 1 |
| Valente, M | 1 |
| Porter, MT | 1 |
| Fluharty, AL | 1 |
| Kiloh, LG | 1 |
| Smith, JS | 1 |
| Williams, SE | 1 |
| Niturad, A | 1 |
| Ciurezu, T | 1 |
| Cucu, I | 1 |
| Escande, M | 1 |
| Vasquez Villareal, S | 1 |
| Gayral, L | 1 |
| Bordeleau, JM | 1 |
| Tétreault, L | 1 |
| Carney, MW | 1 |
| Grove, L | 1 |
| Crammer, JL | 1 |
| van Praag, HM | 1 |
| Dols, LC | 1 |
| Faltus, F | 1 |
| Ginestet, D | 1 |
| Péron-Magnan, P | 1 |
| Meltzer, HY | 1 |
| Thornton, WE | 1 |
| Thornton, BP | 1 |
| Gibson, AC | 1 |
| Kurland, AA | 1 |
| Richardson, JH | 1 |
| Kingstone, E | 1 |
| Vinar, O | 2 |
| Taussigová, D | 2 |
| Bastecký, J | 2 |
| Boleloucký, Z | 1 |
| Neal, CD | 1 |
| Imlah, NW | 1 |
| Grosser, HH | 1 |
| Itil, T | 1 |
| Keskiner, A | 1 |
| Wintrob, RM | 1 |
| Bucci, L | 1 |
| Smulevich, AB | 1 |
| Minsker, EI | 1 |
| Mazaeva, NA | 1 |
| Volkova, RP | 1 |
| Lukanina, SK | 1 |
| Molcan, J | 1 |
| Floreánová, L | 1 |
| Kukucová, H | 1 |
| Motýlová, E | 1 |
| Polák, L | 1 |
| Haddenbrock, S | 1 |
| Kline, NS | 2 |
| Simpson, GM | 2 |
| Swenson, JE | 1 |
| Malm, U | 1 |
| Rasmussen, OS | 1 |
| Fréjaville, JP | 1 |
| Guyochin, A | 1 |
| Gaultier, M | 1 |
| Crane, GE | 1 |
| Glatzel, J | 1 |
4 reviews available for fluphenazine and Dyskinesia Syndromes
| Article | Year |
|---|---|
[COMPLICATIONS DURING CLINICAL THERAPY WITH PSYCHOPHARMACA].
Topics: Agranulocytosis; Autonomic Nervous System Diseases; Chemical and Drug Induced Liver Injury; Chlorpro | 1964 |
The depot fluphenazines: a reappraisal after 10 years' clinical experience.
Topics: Administration, Oral; Adult; Age Factors; Aged; Ambulatory Care; Basal Ganglia Diseases; Child; Dela | 1975 |
Acute dystonia induced by neuroleptic drugs.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease M | 1986 |
Side effects of depot fluphenazines.
Topics: Agranulocytosis; Barbiturates; Basal Ganglia Diseases; Benztropine; Biperiden; Delayed-Action Prepar | 1974 |
15 trials available for fluphenazine and Dyskinesia Syndromes
| Article | Year |
|---|---|
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, | 2004 |
A controlled study of neuroleptization with fluphenazine hydrochloride injections.
Topics: Brief Psychiatric Rating Scale; Clinical Trials as Topic; Double-Blind Method; Fluphenazine; Humans; | 1983 |
Costs and benefits of two doses of fluphenazine.
Topics: Adult; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Sch | 1984 |
Unwanted effects of fluphenazine enanthate and decanoate.
Topics: Autonomic Nervous System; Clinical Trials as Topic; Decanoates; Decanoic Acids; Double-Blind Method; | 1979 |
Tardive dyskinesia treated with pimozide.
Topics: Aged; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Clinical Trials as Topic; Consciousnes | 1975 |
Levodopa in drug-induced extrapyramidal disorders.
Topics: Dihydroxyphenylalanine; Extrapyramidal Tracts; Fluphenazine; Humans; Movement Disorders; Orphenadrin | 1970 |
Benzhexol and side effects with long-acting fluphenazine therapy.
Topics: Administration, Oral; Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Female; Fluphen | 1972 |
Fluphenazine enanthate and fluphenazine decanoate: a comparison of their duration of action and motor side effects.
Topics: Acute Disease; Adult; Aged; Chlorpromazine; Clinical Trials as Topic; Esters; Female; Fluphenazine; | 1973 |
The depot compounds moditen (fluphenazine) and IMAP (fluspirilene) in clinical practice.
Topics: Adolescent; Adult; Clinical Trials as Topic; Delayed-Action Preparations; Drug Evaluation; Fatigue; | 1974 |
A comparative study of two long acting phenothiazine preparations, fluphenazine-enanthate and fluphenazine-decanoate.
Topics: Adult; Behavior; Clinical Trials as Topic; Delayed-Action Preparations; Fluphenazine; Humans; Male; | 1966 |
The use of fluphenazine enanthate in an out-patient clinic.
Topics: Attitude to Health; Clinical Trials as Topic; Fatty Acids; Fluphenazine; Headache; Humans; Movement | 1968 |
Long acting peroral fluphenazine and its dosage in psychoses.
Topics: Adolescent; Adult; Clinical Trials as Topic; Female; Fluphenazine; Humans; Male; Middle Aged; Moveme | 1970 |
Institutional management of chronic schizophrenics with fluphenazine decanoate.
Topics: Chronic Disease; Clinical Trials as Topic; Drug Tolerance; Fluphenazine; Hospitalization; Humans; Ma | 1970 |
Experience of psychiatric management of schizophrenia with fluphenazine decanoate.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Fluphenazine; Humans; | 1970 |
Fluphenazine hydrochloride, enanthate, and decanoate in the management of chronic psychosis.
Topics: Administration, Oral; Chronic Disease; Clinical Trials as Topic; Fluphenazine; Hospitalization; Huma | 1970 |
49 other studies available for fluphenazine and Dyskinesia Syndromes
| Article | Year |
|---|---|
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Ataxia; Avoidance Learning; Brain; Cebus; Chemical Pheno | 1986 |
Effect of Hypericum perforatum on different models of movement disorders in rats.
Topics: Animals; Disease Models, Animal; Fluphenazine; Hypericum; Male; Mastication; Motor Activity; Movemen | 2013 |
Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine.
Topics: Animals; Fluphenazine; Male; Mastication; Movement Disorders; Neuroprotective Agents; Rats; Rats, Wi | 2012 |
Perphenazine suspension: a new, old treatment, side effects and continuous use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Clinical Trials as Topic; Dru | 2012 |
[Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Dose-Response Rel | 2013 |
[SYSTEMATIC COMBINATION OF FLUPHENAZINE AND THIORIDAZINE APROPOS OF 87 CASES].
Topics: Fluphenazine; Humans; Mental Disorders; Movement Disorders; Parkinsonian Disorders; Phobic Disorders | 1963 |
[OBSERVATIONS ON 140 SCHIZOPHRENICS TREATED WITH FLUPHENAZINE. WITH SPECIAL REFERENCE TO DRUG-INDUCED EXTRAPYRAMIDAL SYNDROMES].
Topics: Basal Ganglia Diseases; Extrapyramidal Tracts; Fluphenazine; Humans; Movement Disorders; Parkinsonia | 1963 |
[NEUROLEPTICS AND DYSKINETIC REACTIONS].
Topics: Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chlorprothixene; Depression; Fluphenazine; M | 1963 |
SIDE REACTIONS TO THE PHENOTHIAZINES AND THE THERAPEUTIC USE OF ETHYL ALCOHOL.
Topics: Drug Therapy; Ethanol; Fluphenazine; Movement Disorders; Parasympatholytics; Parkinsonian Disorders; | 1965 |
Considerations for the pre-clinical evaluation of new psychiatric drugs: a case study with phenothiazine-like tranquilizers.
Topics: Aggression; Animals; Ataxia; Behavior, Animal; Catalepsy; Emotions; Extrapyramidal Tracts; Fear; Flu | 1966 |
Side-effects of phenothiazines.
Topics: Adult; Female; Fluphenazine; Humans; Male; Movement Disorders; Perphenazine; Pregnancy; Trifluoperaz | 1967 |
Side-effects of phenothiazines.
Topics: Extrapyramidal Tracts; Fluphenazine; Humans; Movement Disorders; Schizophrenia; Tranquilizing Agents | 1967 |
Neuroleptic drug level monitoring in psychiatry: focus on radioreceptor assay techniques.
Topics: Antipsychotic Agents; Fluphenazine; Humans; Mental Disorders; Movement Disorders; Radioligand Assay | 1982 |
Diagnosis and treatment of Huntington's disease.
Topics: Affective Symptoms; Amitriptyline; Chlorpromazine; Cognition Disorders; Counseling; Deglutition Diso | 1981 |
Neuroleptic medications inhibit complex I of the electron transport chain.
Topics: Animals; Antipsychotic Agents; Electron Transport; Fluphenazine; Movement Disorders; NAD(P)H Dehydro | 1994 |
Neuroleptic-induced striatal damage in rats: a study of antioxidant treatment using accelerometric and immunocytochemical methods.
Topics: Animals; Antioxidants; Antipsychotic Agents; Ascorbic Acid; beta Carotene; Cell Count; Choline O-Ace | 2000 |
Electrophysiology of Purkinje neurons in the weaver mouse: iontophoresis of neurotransmitters and cyclic nucleotides, and stimulation of the nucleus locus coeruleus.
Topics: Acetylcholine; Action Potentials; Animals; Cerebral Ventricles; Cyclic AMP; Cyclic GMP; Electrophysi | 1976 |
The long-acting phenothiazines.
Topics: Antiparkinson Agents; Basal Ganglia Diseases; Cholestasis; Community Mental Health Services; Decanoa | 1975 |
Toxic reactions to lithium and neuroleptics.
Topics: Adult; Drug Therapy, Combination; Fluphenazine; Humans; Lithium; Male; Movement Disorders | 1979 |
Letter: Potentiation of tardive dyskinesia: possible drug interaction.
Topics: Basal Ganglia Diseases; Benztropine; Drug Synergism; Fluphenazine; Humans; Movement Disorders; Tropa | 1975 |
Comparative analysis of persistent dyskinesias of long-term usage with neuroleptics in France and in Japan.
Topics: Adult; Chlorpromazine; Female; Fluphenazine; France; Humans; Japan; Male; Middle Aged; Movement Diso | 1975 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloper | 1976 |
Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters.
Topics: Carbidopa; Catecholamines; Child; Child, Preschool; Fluphenazine; Glycols; Homovanillic Acid; Humans | 1988 |
[Long-term moditen-depot treatment of schizophrenic patients at a psychoneurology dispensary].
Topics: Adult; Affective Symptoms; Ambulatory Care; Antidepressive Agents; Drug Therapy, Combination; Female | 1986 |
Hyperdibasicaminoaciduria in a mentally retarded homozygote with a peculiar response to phenothiazines.
Topics: Adolescent; Amino Acid Metabolism, Inborn Errors; Antipsychotic Agents; Arginine; Chlorpromazine; Cy | 1973 |
Antiparkinson drugs as causal agents in tardive dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Benztropine; Drug Synergism; Female; Fluphenazine; Halop | 1973 |
Maintenance treatment of schizophrenia with long-acting fluphenazine.
Topics: Adult; Chlorpromazine; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Movem | 1974 |
[Incidents and accidents during therapy with long-acting neuroleptics].
Topics: Amenorrhea; Autonomic Nervous System; Body Weight; Delayed-Action Preparations; Depression; Eye Mani | 1974 |
[Study of extrapyramidal manifestations induced by neuroleptics].
Topics: Antiparkinson Agents; Chlorpromazine; Drug Synergism; Extrapyramidal Tracts; Fluphenazine; Haloperid | 1972 |
Letter: Choreiform movements after depot injections of flupenthixol.
Topics: Delayed-Action Preparations; Female; Fluphenazine; Humans; Middle Aged; Movement Disorders; Schizoph | 1974 |
[Long-action neuroleptic agents (delayed-action neuroleptics)].
Topics: Age Factors; Delayed-Action Preparations; Delirium; Fever; Fluphenazine; Hallucinations; Humans; Mov | 1972 |
Rigidity, hyperpyrexia and coma following fluphenazine enanthate.
Topics: Adult; Basal Ganglia Diseases; Benztropine; Catatonia; Coma; Creatine Kinase; Female; Fever; Fluphen | 1973 |
Letter: Tardive dyskinesia and low dosage.
Topics: Chlorpromazine; Fluphenazine; Humans; Hypnotics and Sedatives; Movement Disorders; Promethazine; Psy | 1973 |
Letter: Choreiform movements after depot injections of flupenthixol.
Topics: Adult; Chorea; Ethanol; Female; Fluphenazine; Humans; Injections, Intramuscular; Lithium; Male; Move | 1974 |
Long acting phenothiazines and long term psychotic patients: the role of fluphenazine enanthate in treatment.
Topics: Adult; Aged; Blood Pressure; Body Weight; Delayed-Action Preparations; Female; Fluphenazine; Folklor | 1970 |
Combined intramuscular administration of depot fluphenazine and benztropinemesylate in chronic schizophrenic patients.
Topics: 1-Propanol; Adult; Fluphenazine; Humans; Injections, Intramuscular; Male; Movement Disorders; Parasy | 1971 |
Extrapyramidal symptoms in the course of fluphenazine treatment.
Topics: Adult; Basal Ganglia Diseases; Delayed-Action Preparations; Female; Fluphenazine; Humans; Male; Move | 1972 |
[Characteristics of the psychotropic activity of long-acting drugs (experience in the use of Moditen-depot)].
Topics: Adult; Ambulatory Care; Delayed-Action Preparations; Female; Fluphenazine; Humans; Male; Middle Aged | 1972 |
Therapeutic effect of fluphenazin in various doses and forms.
Topics: Chronic Disease; Dosage Forms; Fluphenazine; Humans; Injections; Liver Function Tests; Movement Diso | 1971 |
[On the mode of action and the question of central organic late damages of continuous neuroleptic treatment].
Topics: Aged; Brain Stem; Butyrophenones; Central Nervous System; Cerebral Ventriculography; Extrapyramidal | 1966 |
Greater than recommended drug dosages--some effects.
Topics: Adult; Extrapyramidal Tracts; Female; Fluphenazine; Humans; Male; Movement Disorders; Procyclidine; | 1970 |
Long-acting, antipsychotic agents and extrapyramidal side effects.
Topics: Delayed-Action Preparations; Extrapyramidal Tracts; Fluphenazine; Humans; Movement Disorders; Parasy | 1970 |
Private ambulatory patients treated with fluphenazine enanthate.
Topics: Ambulatory Care; Bipolar Disorder; Fluphenazine; Humans; Movement Disorders; Schizophrenia | 1970 |
Intramuscular long-acting fluphenazine in the treatment of schizophrenia.
Topics: Administration, Oral; Adult; Aged; Chlorpromazine; Chronic Disease; Fluphenazine; Haloperidol; Human | 1970 |
Fluphenazine enanthate in sesame oil, a depot preparation.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Female; Fluphenazine; Huma | 1970 |
[152 cases of acute poisoning by phenothiazine amines].
Topics: Absorption; Adolescent; Adult; Aged; Agranulocytosis; Anesthesia, General; Anesthesia, Obstetrical; | 1970 |
Dyskinesia and neuroleptics.
Topics: Adult; Chlorpromazine; Chronic Disease; Fluphenazine; Hospitalization; Humans; Male; Middle Aged; Mo | 1968 |
[On the problem of the therapeutical axis symptom of neuroleptic medicaments].
Topics: Adult; Extrapyramidal Tracts; Fluphenazine; Haloperidol; Handwriting; Humans; Male; Movement Disorde | 1968 |
Fluphenazine: twelve years' experience.
Topics: Female; Fluphenazine; Humans; Mental Disorders; Movement Disorders; Pregnancy; Schizophrenia | 1968 |